|Mr. Richard Anthony Moulson||CFO & Exec. Director||85.4k||N/A||1962|
|Dr. Huw Jones||Chief Exec. Officer||N/A||N/A||1960|
|Ms. Liz Jenkins||Regulatory Consultant||N/A||N/A||N/A|
|Dr. Thomas Morris||Consultant & Medical Advisor of Oncology||N/A||N/A||N/A|
|Prof. Albena Dinkova-Kostova||Independent Scientific Advisor||N/A||N/A||N/A|
|Prof. Giovanni Mann||Independent Scientific Advisor||N/A||N/A||N/A|
Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.
Evgen Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.